![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Assessment of Drug-Drug Interactions Between
Daclatasvir and Darunavir/Ritonavir or Lopinavir/Ritonavir
|
|
|
Reported by Jules Levin
16th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy. Washington DC, May 26-28, 2015
Gandhi Y, Adamczyk R, Wang R, Stonier M, Kandoussi H, Hesney M, Liu Z, Ackerman P, Garimella T, Eley T
Bristol-Myers Squibb Research & Development, Princeton, NJ
![Pharm1.gif](../images/060315/060315-1/Pharm1.gif)
EASL: Daclatasvir Plus Sofosbuvir for Treatment of HCV Genotypes 1-4 in HIV-HCV Coinfection: The ALLY-2 Study - (04/28/15)
Daclatasvir: Overview of Drug-Drug Interactions With Antiretroviral Agents and Other Common Concomitant Drugs........[Eley T et al. HIV DART 2014] ........http://www.natap.org/2014/HCV/121714_01.htm
![Pharm2.gif](../images/060315/060315-1/Pharm2.gif)
![Pharm3.gif](../images/060315/060315-1/Pharm3.gif)
![Pharm4.gif](../images/060315/060315-1/Pharm4.gif)
![Pharm5.gif](../images/060315/060315-1/Pharm5.gif)
![Pharm6.gif](../images/060315/060315-1/Pharm6.gif)
![Pharm7.gif](../images/060315/060315-1/Pharm7.gif)
![Pharm8.gif](../images/060315/060315-1/Pharm8.gif)
![Pharm9.gif](../images/060315/060315-1/Pharm9.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|